Capricor Therapeutics (CAPR) Reiterates Overweight Rating Ahead of Upcoming PDUFA

July 7, 2026 7:18 AM

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $62.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found